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Abstract: Transitional cell carcinoma (TCC) is the second most common urologic malignancy, 
and 70% of patients present with superficial or nonmuscle invasive bladder cancer (NMIBC). 
Intravesical bacillus Calmette-Guerin (BCG) is the most effective agent for preventing disease 
recurrence, and the only therapy able to inhibit disease progression. However, recurrence rates 
as high as 30% and significant local and systemic toxicity have led to increased interest in 
alternative intravesical therapies. In patients refractory or intolerant to BCG, BCG-interferon 
α2b, gemcitabine, and anthracyclines (doxorubicin, epirubicin, valrubicin) have demonstrated 
durable clinical responses. Phase I trials investigating alternative cytotoxic agents, such as 
apaziquone, taxanes (docetaxel, paclitaxel), and suramin are reporting promising data. Novel 
immunomodulating agents have demonstrated promise as efficacious alternatives in patients 
refractory to BCG. Optimization of existing chemotherapeutic regimens using hyperthermia, 
photodynamic therapy, magnetically-targeted carriers, and liposomes remains an area of active 
investigation. Despite enthusiasm for new intravesical agents, radical cystectomy remains the 
treatment of choice for patients with NMIBC who have failed intravesical therapy and selected 
patients with naïve T1 tumors and aggressive features. This report provides a comprehensive 
review of contemporary intravesical therapy for NMIBC and refractory NMIBC, with an 
emphasis on emerging agents and novel treatment modalities.
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Introduction
Bladder cancer is the fourth most common malignancy among men in the Western 
world.1 More than 90% of bladder cancer diagnoses are made in patients older than 
55 years of age, with a three-to-one male to female predominance.2 Transitional cell 
carcinomas (TCC) predominate, with superficial or nonmuscle invasive bladder cancers 
(NMIBC) found at diagnosis in more than 70%.3
Transurethral resection (TUR) facilitates accurate tumor grading and staging, pro-
vides local disease control, and is typically performed for the management of newly 
diagnosed TCC. Following TUR alone, TCC recurs or progresses in 50%–80% and 
14%, respectively, despite adequate resection.4 The risk of disease recurrence and 
progression is highly variable, and risk-stratification based on pathologic and clinical 
variables is commonly utilized for more accurate prediction.5
The perioperative instillation of chemotherapy immediately following TUR 
has been advocated to destroy residual microscopic tumor cells and to prevent 
 re-implantation.6 Intravesical therapy has also been employed in an induction and/or 
maintenance fashion to provide long-term immuno-stimulation of chemotoxicity in 
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an effort to prevent disease recurrence.7 The high rate of 
tumor recurrence in patients with NMIBC mandates  lifetime 
surveillance and leads to high health care related costs 
despite the use of adjuvant intravesical therapy.8 We review 
intravesical treatment strategies, discuss modes of efficacy 
enhancement, and explore the role of novel agents in the 
management of NMIBC.
Immunomodulators
Immunotherapeutic strategies produce antitumor effects 
via either passive or active immunity.9 Enhancing active 
immunity, ie, recruitment and imprinting of the host immune 
system to recognize and effectively destroy tumor cells, 
is the focus of most of the current work in bladder cancer 
immunotherapy. Interleukins (ILs), which contribute to the 
host immune response by stimulating T-cell and natural 
killer (NK) cell proliferation and cytokine production, have 
been shown to have antitumor activity in animal models,10 
and investigators were hopeful that adjunctive IL therapy 
would improve the efficacy of traditional intravesical agents.9 
However, initial trials utilizing IL-2,11 IL-12,12 tumor 
 necrosis factor (TNF),13 and granulocyte macrophage colony 
 stimulating factor (GM-CSF)14 demonstrated poor evidence 
of tumor response, local and systemic side effects, and early 
disease recurrence.
Bacillus Calmette-Guerin
BCG, an attenuated mycobacterium developed as a vaccine 
for tuberculosis, has been shown to have significant antitumor 
activity against many different malignancies.6 First described 
by Morales for the treatment of superficial bladder cancer 
nearly 20 years ago,13 its use in the treatment of NMIBC has 
gained widespread acceptance in the urologic community. 
The action of BCG is based on inducing cytokine release in 
the urine and bladder wall, resulting in the chemoattraction 
of granulocytes and mononuclear cells. Although the exact 
mechanism of action is debatable, the initial step appears to 
be the binding of fibronectin, facilitating attachment to the 
urothelium and subsequent incorporation of glycoproteins 
into the bladder wall. The resulting nonspecific immune 
stimulation leads to release of macrophages, T-lymphocytes, 
B-lymphocytes, NK cells, and various cytokines. Cytokine 
release (interferon-γ, IL-2, and TNF) induces a TH
1
-mediated 
response and antitumor activity.6,15
Intravesical administration of BCG as induction therapy 
for NMIBC has been shown to delay the time to first recur-
rence compared with TUR alone.6 Shelley et al reviewed six 
randomized trials comparing TUR alone versus  TUR-BCG 
in patients with Ta and T1 bladder cancer. Using tumor 
 recurrence as their outcome of interest, their analysis revealed 
a significant advantage in patients treated with BCG fol-
lowing TUR over TUR alone.16 A recent meta-analysis of 
24 randomized clinical trials including nearly 5000 patients 
with carcinoma in situ (CIS), Ta, or T1 TCC reported that 
BCG reduced the odds of disease progression by 27% com-
pared with TUR alone or resection and another treatment 
other than BCG. Of importance, these benefits were only seen 
in patients receiving maintenance therapy and there was no 
effect on overall or disease-specific survival.6,17
Induction treatment regimens of BCG typically begin 
two to four weeks following resection and are most com-
monly administered weekly for six weeks. However, there 
is debate as to the optimal dosing schedule, and controversy 
persists regarding the role of maintenance therapy and 
its long-term effect on recurrence and progression.18 In a 
randomized, prospective trial, 550 patients with NMIBC 
or CIS were randomized to a maintenance therapy arm or 
no maintenance therapy following a six-week induction 
course of BCG. Findings demonstrated a significant differ-
ence in median recurrence-free survival in the maintenance 
therapy arm (76.9 versus 35.7 months, P , 0.0001) and a 
5% improvement in five-year overall survival (P = 0.08) 
with a median follow-up of 120 months.19 Initial reports from 
large meta-analyses suggest that maintenance therapy should 
be administered, but the optimal schedule and duration of 
therapy remains undetermined.6,7,17,20
The use of BCG can be limited by its side effect profile 
and subsequent intolerance that occurs in approximately 
20% of patients during maintenance therapy.21 BCG toxicity 
includes local and systemic reactions, ranging from cystitis, 
hematuria, bladder contracture, and mild flu-like symptoms, 
to life-threatening sepsis.22 However, findings of recent large 
meta-analyses suggest that while the toxicity with BCG 
is higher than with intravesical chemotherapy, systemic 
effects do not predict efficacy,23 and there is no difference 
in toxicity between induction and maintenance regimens.24,25 
Some recent trials have demonstrated that a reduced regimen 
(one-third dose) may be as effective as standard dosing with 
fewer side effects.26,27
Concern regarding BCG-related toxicity and disease 
progression has led to the study of other intravesical 
 chemotherapeutic agents (Table 1) in the treatment of 
NMIBC, most notably mitomycin C (MMC).9 However, large 
meta-analyses examining patients with Ta and T1 TCC have 
concluded that BCG is superior to intravesical chemotherapy 
in preventing tumor recurrence in patients at high risk28,29 
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Table 1 emerging immunomodulating and cytotoxic intravesical agents currently under investigation
Agent Mechanism Advantages Disadvantages Toxicity
Immunomodulating agents
iFN (+ BCG) T-Helper Type i cell  
and NK cell stimulation,  
MHC i antigen  
expression
a) increased efficacy 
b) salvage therapy 
c)  efficacy not affected  
by prior BCG  
exposure
a) costly
b)  loss of prognostic  
information provided by 
response to BCG 
monotherapy
mild to moderate local adverse 
effects
Bropirimine Aryl pyrimidine that 
augments endogenous 
iFN production
a)  powerful antitumor 
properties
a)  significant hematologic  
and systemic toxicity
cardiac effects*
Keyhole-Limpet 
hemocyanin
Nonspecific immune 
stimulator
a) lacks toxicity
b)  greater efficacy 
than MMC
c) minimal side effects
a)  unclear protection  
against disease 
progression
b) optimal dosing not defined
safe and well tolerated
Mycobacterial cell 
wall complexes
Nonspecific immune 
stimulator 
induction of apoptosis
a)  eplicates efficacy of 
BCG without the  
side effects
a) side effects ill-defined mild to moderate local adverse 
effects
Mistletoe lectin induces cytokine release, 
increases lymphocyte 
activation marker 
expression
a) safe a)  clinical efficacy not yet  
defined
safe and well tolerated
Chemotherapeutic agents
Gemcitabine Pyrimidine analog that 
inhibits cell growth  
and induces 
apoptosis
a) salvage therapy
b)  minimal systemic 
absorption and  
toxicity
c) prophylactic efficacy
a) myelosuppression 
b) anemia
mild to moderate local adverse 
effects
Anthracyclines Topoisomerase ii 
inhibitor
a) increased efficacy 
b) inexpensive
c) safe
Efficacy of maintenance  
therapy unknown 
mild to moderate local adverse 
effects†
Apaziquone Alkylating agent a)  not cell-cycle  
specific 
a)  frequent side effects  
(leukopenia, irritative  
voiding symptoms) 
mild to moderate local adverse 
effects
Taxanes Microtubule 
polymerization 
inhibitor
a)  no systemic  
absorption
b) limited toxicity
a) poor aqueous solubility 
b) limited clinical experience 
mild to moderate local adverse 
effects
Suramin veGF antagonist a)  limited local and 
systemic toxicity
a) limited clinical experience metabolic, hematologic, renal 
and  neurologic sequelae 
(systemic  administration);  
minimal effects  with  
intravesical adminstration
Abbreviations: Ab, antibody; NK, natural killer; MHC, major histocompatability complex; veGF, vascular endothelial growth factor.
*Discontinued by manufacturer in 1996 due to cardiac toxicity; †Synthetic derivatives epirubicin and valrubicin show improved local toxicity profiles.
and when maintenance therapy is utilized.17,30 Sylvester et al 
reviewed nine randomized trials including 700 patients with 
CIS treated with either BCG or intravesical chemotherapy 
(MMC, epirubicin, adriamycin, or combination therapy). 
With a median follow-up of 3.6 years, the researchers con-
cluded that intravesical BCG significantly reduces the risk 
of short- and long-term treatment failure compared with 
intravesical chemotherapy and that BCG is first-line therapy 
for treatment of CIS.31 Further review of these analyses has 
led to the current American Urological Association (AUA) 
consensus that an induction course of BCG followed by 
maintenance therapy is recommended for the treatment of 
high-grade Ta or T1 TCC and CIS.6,7,9
Although currently f irst-line therapy for high-risk 
NMIBC, five-year recurrence rates are estimated to be 34% 
in patients receiving BCG maintenance therapy.7 The  efficacy 
of BCG is also hampered by side effects and treatment 
 intolerance, as well as the risks of understaging or progression 
to muscle-invasive disease. Radical cystoprostatectomy and 
urinary diversion is currently the standard of care for muscle-
invasive TCC,32 and there is growing consensus that relative 
indications for early cystectomy include recurrent NMIBC 
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refractory to intravesical therapy and naïve T1 disease with 
high-risk features for tumor progression.33 However, the risk 
of perioperative complications and morbidity associated with 
cystectomy has spawned further interest in the utility of novel 
intravesical agents for BCG refractory disease.6
interferon
Interferon (IFN) α2b has been utilized as both monotherapy 
and adjunct therapy in BCG-refractory patients.6,9 IFNs are 
glycoproteins that mediate the host immune response in a 
dose-dependent manner by increasing antibody responsive-
ness, stimulating NK cells, and inducing expression of Class I 
major histocompatibility complex antigens.9,34 The results 
of early investigations of IFN as monotherapy to prevent 
disease recurrence have been disappointing, demonstrating 
no benefit or inferior recurrence rates when compared with 
placebo controls35 or other intravesical agents (BCG, MMC, 
MMC-IFN).6,36
In contrast, results from initial trials investigating the 
combination of IFN-BCG have been more promising.6 
O’Donnell et al reviewed their experience utilizing BCG 
plus 50 million units of IFN in 40 patients who had relapsed 
following induction BCG therapy.9 With a mean follow-up 
of 30 months, 63% and 53% recurred at one and two years, 
respectively.37 In a multicenter Phase II trial, BCG-IFN was 
administered to 536 BCG-naïve patients and 467 BCG-
refractory patients with NMIBC. With a median follow-up 
of 24 months, recurrence-free rates were 59% and 45% in 
the BCG-naïve and BCG-refractory groups,  respectively.6 
Factors associated with tumor recurrence were tumor 
size . 5 cm, prior BCG failure, and tumor multifocality.38 
In a recent subanalysis of the same cohort, Gallagher et al 
reported that BCG-refractory patients who relapsed more 
than one year following induction therapy had similar 
response rates to those of BCG-naïve patients.6 However, 
recurrence rates were higher in those with recurrent disease 
less than one year following induction therapy.39 The use of 
BCG-IFN as initial therapy is limited and currently there is 
no consensus regarding the benefit of the addition of IFN in 
BCG-naïve patients.40 Based on the available data, BCG-IFN 
appears to be a well-tolerated alternative to salvage therapy 
in selected patients with BCG-refractory NMIBC, but radical 
treatment options should be pursued for early failures and 
true BCG-refractory disease.9
emerging agents under investigation
Bropirimine is a broad-spectrum immunostimulatory 
 compound with oral absorption and urinary excretion.6 
Although not currently available in the US, the findings of a 
recent clinical trial demonstrated equivalent response rates 
to BCG in 55 BCG-naïve patients with CIS.41 The results 
of a Phase II trial examining the utility of bropirimine in 
86 BCG-refractory patients reported a complete response in 
24% of patients, with a 6% rate of progression to muscle-
invasive disease or metastasis.42 However, a recent Southwest 
Oncology Group Phase II trial investigating combination 
bropirimine-BCG therapy in 51 BCG-naïve patients with 
CIS reported discouraging five-year progression-free (53%) 
and overall survival (80%) rates, and recommended that 
no further evaluation of this combination be conducted.43 
Bropirimine was discontinued by the manufacturer in 1996 
due to significant concerns regarding cardiac toxicity and is 
currently not under clinical investigation in NMIBC.9
Keyhole limpet hemocyanin (KLH) is a highly  antigenic 
respiratory pigment of the mollusk Megathura cranu-
lata that results in nonspecific immune stimulation.44 
 Attractive as an alternative to BCG due to its limited side 
effect profile, there have been several small Phase I and II 
clinical trials  investigating its use as an intravesical agent.9 
 Jurincic-Winkler et al treated 13 Tis patients with six weeks of 
KLH induction monotherapy, monthly treatments for one year, 
and bimonthly treatments for the two  following years, report-
ing two complete responses at 66 and 82 months.9,45  However, 
patients not responding to two KLH treatments were managed 
with BCG, and most patients exhibited disease progression 
regardless of therapy. In a multicenter study, Lamm et al 
reported a durable response in 64 patients with Tis (50%) 
and residual Ta-T1 disease (20%) treated with escalating 
doses of KLH for six weeks.46 Despite promising results, 
comparative studies with BCG and chemotherapeutic agents 
(MMC, ethoglucid) have not demonstrated a benefit with KLH 
in patients with refractory NMIBC,47,48 and further investiga-
tion is necessary before KLH can be recommended in patients 
refractory or intolerant to BCG.9
As a live bacterium, BCG carries the potential for 
 significant adverse effects of varying clinical severity. 
In an effort to minimize these reactions, researchers have 
investigated using reduced dosages, adjunctive  antibiotics, 
or heat/radiation-inactivated bacteria, with minimal 
success.9,49  However, recent work investigating the use of 
 Mycobacterium phlei  mycobacterial cell wall complexes 
(MCC) containing mycobacterial DNA has generated 
significant interest.9 A dual mechanism of action has been 
postulated, with both immunomodulatory (similar to BCG) 
as well as chemotherapeutic apoptotic features.50 Early 
clinical work utilizing an MCC emulsion in 61 patients 
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with Tis over a 48-week duration demonstrated a partial or 
 complete response rate in 52% of BCG-refractory patients 
and 69% of BCG-naïve patients with acceptable side effects.51 
 Subsequent work has resulted in a new product formulation 
which still contains mycobacterial DNA but without the toxic 
 preservative thimerosal.49 This formulation is currently being 
investigated in 55 patients with CIS (30% had additional 
papillary tumors), 25 of whom received 4 mg MCC per treat-
ment, and 30 received 8 mg MCC per treatment on similar 
schedules. Early results demonstrate an encouraging initial 
complete response rate (27%–46%) at weeks 12 and 26 in both 
treatment groups, whereas response rates were more marginal 
at 18 months follow-up (23%–32%) and were comparable 
between BCG-refractory and BCG-naïve patients.52 Based 
on these early promising results, patients are currently being 
enrolled for clinical trials examining the efficacy of MCC in 
high-grade nonmuscle invasive lesions refractory to BCG as 
well as in BCG-naïve patients at high risk for recurrence or 
progression.49
A recombinant form of mistletoe lectin, another potential 
immunotherapeutic agent, is currently under development. 
By stimulating the release of cytokines and expression of lym-
phocyte activation markers, mistletoe lectin has been shown 
to inhibit urothelial carcinogenesis in rat models.53 In the first 
clinical application, Goebell et al  randomized 45 patients with 
pTa G1–2 TCC to a single adjuvant mistletoe lectin treat-
ment two weeks following TUR versus no adjuvant therapy. 
At 18 months’ follow-up, there were no significant differ-
ences with respect to recurrence-free interval or the number 
of recurrences between groups.54 However, in a subsequent 
Phase II study examining use of mistletoe lectin induction 
therapy in 30 patients with NMIBC, Elsasser-Beile et al 
reported no local or systemic side effects and a 33% recur-
rence rate at 12 months, which was comparable with findings 
in an historical control group of patients undergoing BCG 
induction therapy. While further investigation is  warranted to 
determine the optimal dose and timing of treatment, mistletoe 
lectin may ultimately prove to be a better tolerated alternative 
to BCG in selected patients.55
Gene therapy
Gene therapy has several theoretical advantages over 
conventional intravesical therapies, including a high 
 selectivity for tumor cells with mutated genes, potential to 
restore normal cell growth by correcting genetic defects, 
and potential to reduce chemoresistance.6,56 Gene  delivery 
 systems include both viral (adenovirus, vaccinia) and 
nonviral vectors (lipoplexes, Table 2). While the relative 
advantages/disadvantages of each method of gene delivery 
is beyond the scope of this review, the inadvertent systemic 
absorption of viral vectors resulting in an excessive immune 
response is a significant concern that may be avoidable with 
the utilization of intravesical or nonviral vectors.6,57 Viral 
receptor expression and physical composition of  urothelial 
surface cells are formidable barriers to the delivery of 
intravesical gene therapy. Current research efforts have 
been directed at modulating coxsackie-adenovirus receptor 
expression,58 as well as coadministration of the polyamide 
syn3 to disrupt the urothelial barrier,59 thereby increasing 
viral uptake and improving adenoviral therapy efficacy. Use 
of replication-competent viral systems is also being explored 
in animal models, but concerns include infection of non-
targeted cells and the  potential for carcinogenic insertional 
mutagenesis.56
Early in vivo and in vitro studies have shown promising 
results. Using a rat model, Conner et al demonstrated the effi-
cacy of adenoviral-mediated gene-delivered IFN therapy to 
inhibit bladder cancer growth, with increased drug concentra-
tions and retention times compared with standard intravesical 
instillation.60 Utilizing a replication-competent oncolytic adeno-
virus (CG0070) encoding GM-CSF, Ramesh et al demonstrated 
selective replication, cytotoxicity, GM-CSF production, and 
antitumor efficacy in both in vitro and in vivo bladder TCC 
models compared with normal human cells.61 Recombinant 
vaccinia virus delivery of a p53 gene in an orthotopic mouse 
bladder tumor model provided a survival advantage compared 
with phosphate buffer or empty vector control groups.62 In a 
murine bladder tumor model, Lee et al examined the efficacy 
of recombinant BCG and murine IL-12 DNA vaccines using 
eukaryotic expression vectors.6 The cumulative survival of mice 
treated with both the BCG vaccine and the IL-12 vaccine was 
significantly higher compared with that of controls or those 
treated with either vaccine alone.63 Horinaga et al administered 
intravesical IL-12 gene therapy delivered in cationic liposome 
vector in a mouse model with orthotopic bladder tumors.6 
When compared with a high-dose BCG-treated group and 
negative controls, IL-12 therapy was equivalent to BCG, and 
both treatments were superior to the reporter gene-negative con-
trols.6 Interestingly, surviving IL-12-treated mice rechallenged 
with additional tumor cell implantation after 60 days survived 
 significantly longer than BCG-treated mice, suggesting a more 
durable tumoricidal effect.64
Early Phase I clinical trials have demonstrated that intra-
vesical gene therapy can be safely administered in bladder 
cancer patients with minimal toxicity. In four patients with 
muscle invasive bladder cancer, Gomella et al administered 
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three increasing doses of intravesical DryVax (Wyeth-Ayerst 
Laboratories, Philadelphia, PA), a DNA poxvirus, prior 
to cystectomy.65 Histologic examination of the bladders 
24 hours following the last dosing revealed evidence of viral 
infection in both tumor and normal cells, and a significant 
mucosal and submucosal inflammatory reaction in both tumor 
and normal tissue.6 There were no clinical or laboratory 
manifestations of vaccinia-related toxicity with the exception 
of mild dysuria. In patients with histologically confirmed 
TCC, Kuball et al administered an intratumoral injection or 
intravesical instillation of an adenoviral vector containing 
wild-type p53 with a gene transfer enhancer (SCH 58500) 
in 11 patients prior to cystectomy. Specific transgene expres-
sion was detected in tumors and normal bladder samples in 
7/8 patients treated intravesically, but was not seen in patients 
receiving  intratumoral injection. No cases of dose-limiting 
toxicity were observed and side effects were transient.6,66 
In a feasibility study, Pagliaro et al administered repeated 
doses of adenoviral vector-mediated p53 (Ad5CMV-p53) 
to 13 patients with locally advanced TCC who were not 
candidates for cystectomy. The treatment was well tolerated 
by all patients and specific transgene expression was found 
in 2/7 patients.67 Emerging therapies currently being inves-
tigated include gene therapy using viral and nonviral vectors 
for transfer, monoclonal antibodies, and direct tumoricidal 
viruses. While there is currently little evidence demonstrat-
ing a clinical benefit in human studies, gene therapy remains 
an exciting field for future investigation, and the further 
development of alternative vector systems will help define 
a therapeutic role in the management of NMIBC.
Table 2 investigational genetic therapies for the management of NMiBC
Agent Mechanism Advantages Disadvantages
Gene therapy
 vectors
  Adenovirus Cell entry via the  
coxsackie/adenovirus  
membrane receptor
a)  DNA does not integrate into  
host chromosomes
b)  ease of obtaining recombinant 
proteins and producing vectors 
in high titers
c)  high viability of host cells 
 post-infection
a) poor viral uptake
b)  inadvertent systemic absorption  
may elicit excessive immune 
response or insertional  
mutagenesis in host cells
  vaccinia Recombinant double-stranded  
DNA virus
a) broad applicability
b) rapid infection
c)  efficient transgene  
expression
a)  vaccination against small pox 
may inhibit gene transfer
  Nonviral (lipoplexes) ionic cellular uptake a) simple preparation
b) inexpensive
c) low immunogenicity
d) carry larger genes
a) poor cell uptake and transfer
Monoclonal antibodies  
(Thrombospondin-1, eGF receptor)
Reduce tumor angiogenesis  
and induce apoptosis
a) simple preparation 
b) highly specific 
c) low immunogenicity
a) Lack of adequate delivery vehicle
Hemagglutinating virus of Japan  
envelope factor (HvJ-e)
induces extensive immunologic 
antitumor activity
a)  no need for concurrent 
chemotherapy administration
a) investigational 
b) poor specificity
siRNA Silences targeted gene  
expression on the  
mRNA level 
a) specificity 
b) high efficiency
a) insertional mutagenesis
b) iatrogenic leukemia
c)  inefficient cellular uptake and 
local delivery
 Therapeutic targets
  p53 Dysregulation of apoptosis;  
direct lytic effect
  iFN-α inhibits tumor proliferation;  
induces differentiation
  iL-10 Suppresses APC capacity
  CG0070 Preferential GM-CSF  
production activates host immune 
response
Abbreviations: NMiBC, nonmuscle invasive bladder cancer; iNFα, interferon alpha; APC, antigen presenting cell; iL, interleukin; GM-CSF, granulocyte macrophage colony 
stimulating factor; eGF, epidermal growth factor.
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Chemotherapeutic agents
The use of intravesical chemotherapeutic agents for NMIBC 
has been met with variable success.68 Traditionally reserved 
for use in patients with BCG-refractory disease, multiple 
agents, most commonly MMC, epirubicin, and valrubicin, 
are currently being investigated as primary and secondary 
therapy for NMIBC.6 Early data suggested that the addition 
of intravesical chemotherapy to TUR yields a 14% reduction 
of tumor recurrence but has limited benefit with respect to 
disease progression.69 However, in two recent meta-analyses 
examining the impact of multiple intravesical chemothera-
peutic agents on recurrence prevention, Huncharek reported 
that recurrence rates may be reduced by as much as 70% 
when compared with TUR alone.6 Variations in dosage and 
treatment schedules were postulated to account for the large 
differences in recurrence rates observed across studies.70,71 
Current efforts are focused on defining the ideal treatment 
schedule, optimizing the efficacy of traditionally utilized ther-
apies, and investigating novel chemotherapeutic agents.
Mitomycin C
MMC is a cross-linking agent that inhibits DNA synthesis.72 
Due to its high molecular weight (329 kDa), there is reduced 
risk of transurothelial absorption and side effects are minimal 
even in the immediate postoperative period.9,73 Currently, the 
dosage varies from 20 to 60 mg per instillation.6 The most 
commonly used dose is 40 mg in 40 mL of saline or sterile 
water administered weekly for eight weeks followed by 
monthly instillations for one year.7 Initial studies investigating 
the use of MMC as monotherapy for NMIBC following TUR 
showed promising results.74,75 In a small prospective trial, 
Huland et al randomized 58 patients with NMIBC following 
TUR to either no further therapy or MMC at 20 mg/20 mL 
instilled every two weeks for the first year and every four 
weeks for the second year. Although patients with superfi-
cial low-grade tumors were probably included,  recurrence 
rates with MMC (7%) were significantly lower compared 
with the control group (50%).76 Tolley et al  randomized 
502 patients following TUR to no adjuvant treatment, one 
perioperative instillation of MMC, and up to five MMC 
instillations at three-month intervals following resection. 
With a median follow-up of five years, the authors reported 
decreased recurrence rates and an increased recurrence-free 
interval in patients undergoing MMC therapy, with evidence 
to suggest a slight advantage of multiple instillations over 
one perioperative instillation.6,77
Signif icant attention is currently being directed 
towards defining the optimal MMC treatment schedule, 
and identifying which patients will benefit from a single 
perioperative treatment compared with chronic mainte-
nance therapy.6 Chemotherapeutic agents are preferred to 
BCG in the immediate perioperative period due to reduced 
risks of systemic absorption following TUR. Tolley et al 
reported a significant decrease in tumor-recurrence risk in 
patients with NMIBC treated with a perioperative (less than 
24 hours following TUR) 40 mg MMC treatment compared 
with TUR alone.77 Benefits of a single immediate instil-
lation on the risk of tumor recurrence have been reported 
with epirubicin78 and doxorubicin79 as well, although 
optimal timing post-TUR has not been determined. In a 
meta-analysis of seven randomized trials comparing TUR 
alone with TUR plus one immediate instillation of chemo-
therapy, Sylvester et al reported a 39% reduction in risk of 
recurrence (odds ratio [OR] 0.61, P , 0.0001). Benefits 
were seen in patients with a single tumor or with multiple 
tumors. However, recurrence was higher in patients with 
multiple tumors compared with solitary tumors (65.2% 
versus 35.8%).80 Based on these data, the current AUA 
superficial bladder cancer guidelines recommend that a 
single dose of intravesical chemotherapy be administered 
immediately postoperatively (less than six hours) in 
patients with small volume solitary tumors when there is 
no evidence of bladder perforation.7 Currently consensus 
is lacking regarding effectiveness of perioperative MMC 
on decreasing recurrence rates compared with other che-
motherapeutic agents.6
In patients with intermediate- and high-risk NMIBC, 
induction therapy is recommended to prevent disease 
recurrence.7 The literature currently supports the superior-
ity of BCG in limiting disease recurrence and progression 
compared with chemotherapeutic agents.31 However, BCG 
toxicity limits its use in a significant number of patients, 
resulting in an increasing need for alternative thera-
pies. In a meta-analysis of six trials comparing BCG and 
MMC in 1527 patients, Shelley et al reported a reduced 
incidence of local (30% versus 44%) and systemic toxicities 
(12% versus 19%) with MMC, with no significant difference 
in recurrence, progression, or survival. While the overall 
analysis, which included low-risk patients, failed to show 
a difference in risk of recurrence, a subgroup analysis of 
three trials including only patients with high-risk NMIBC 
revealed a 31% reduced risk of tumor recurrence with 
BCG compared with MMC.6,28,29 Additional meta-analyses 
have demonstrated that maintenance BCG is required to 
see the greatest benefit in reducing tumor recurrence and 
 progression when compared with MMC.6,24,30
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Until recently, there was general consensus that 
 chemotherapy was effective in reducing short-term risk 
for recurrence but its efficacy was only marginal in the 
long term.79,81,82 However, in a recent prospective trial, 
Friedrich et al randomized 495 patients with  intermediate- to 
high-risk NMIBC following TUR to a six-week course of 
BCG, a six-week course of MMC, or a six-week course of 
MMC followed by monthly instillations for three years. 
Three-year recurrence-free rates were 65.5% for short-term 
BCG, 68.6% for short-term MMC, and 86.1% for patients 
undergoing long-term MMC therapy,83 supporting the 
potential use of MMC maintenance therapy as an alternative 
to BCG in high-risk populations. Current efforts are being 
directed towards optimizing the efficacy of chemotherapeutic 
agents and will be discussed later in this review.9
Thiotepa
Thiotepa, an alkylating agent that inhibits nucleic acid 
synthesis by inducing the cross-linkage of DNA, RNA, and 
proteins,84 is currently the only chemotherapeutic agent 
approved by the Food and Drug Administration for  papillary 
TCC.6 Dosing ranges from 30 mg in 30 mL to 60 mg in 
60 mL sterile water or saline, with six- to  eight-weekly instil-
lations followed by administration monthly for one year.6 
Risks of local toxicity such as irritating voiding symptoms 
are prevalent, and there is a significant risk of systemic 
 myelosuppresion requiring frequent leukocyte and platelet 
count monitoring due to the low molecular weight of thiotepa 
(189 kDa).85
Initial trials demonstrated the efficacy of thiotepa in 
preventing recurrence when compared with controls.84,86 
However, subsequent trials have demonstrated inferior 
results when thiotepa is compared with MMC85 or BCG. 
 Martinez-Pineiro et al reported the results of a  prospective 
trial in which patients with NMIBC were randomized to 
15 courses of intravesical doxorubicin 50 mg, thiotepa 
50 mg, or BCG 150 mg following TUR.87 With three years 
of follow-up, patients randomized to BCG demonstrated 
a significant reduction in risk of recurrence (13.7%) when 
compared with thiotepa (35.7%) or doxorubicin (43.4%).6 
A similar trend was seen when patients were stratified by 
stage of disease. Review of these initial studies identified 
nine controlled trials including 1130 patients. Reviewing 
five of the trials that achieved statistical significance,84,88–91 
the mean rate of recurrence in the control populations was 
61% versus 49% in the treated groups, resulting in a modest 
12% benefit with thiotepa therapy.69 Currently, due to its 
marginal efficacy and risk of systemic toxicity, use of thiotepa 
is limited to patients who cannot tolerate BCG or selected 
BCG-refractory cases not medically fit for cystectomy.6
Gemcitabine
Gemcitabine is a pyrimidine analog that exhibits antitumor 
activity by inhibiting cell growth and triggering apoptosis, 
and is currently a staple in the systemic chemotherapeutic 
regimens utilized in metastatic and locally advanced TCC.6,9,92 
Phase I trials have reported that the high molecular weight of 
gemcitabine (299.66 kDa) prevents systemic toxicity with an 
intact bladder,93 and the ablative efficacy of gemcitabine has 
also been demonstrated in early tumor marker studies.94
Phase II clinical trials are currently underway investigat-
ing the efficacy of intravesical gemcitabine following TUR 
for NMIBC.9 In 116 patients undergoing weekly dosing for 
six weeks following TUR, Bartoletti et al reported recurrence 
rates of 25.9% and 77.1% in patients with intermediate- 
and-high risk disease, respectively.95 With a novel pre- and 
post-TUR dosing scheme in nine patients with persistent or 
recurrent Ta-1, Grade 1–2 TCC following previous intravesi-
cal therapy, Mattioli et al reported recurrence in 77.7% of 
patients.96 Dalbagni et al recently reported their observations 
in 30 patients who were either refractory or intolerant to BCG 
and treated with twice-weekly gemcitabine for three weeks. 
With a median follow-up of 19 months, 50% achieved a com-
plete response, 40% relapsed with a median recurrence-free 
survival of 3.6 months, and 37% progressed to cystectomy.97 
A randomized Phase III clinical trial of gemcitabine versus 
MMC in recurrent bladder cancer revealed 72% and 61% 
disease-free recurrence rates in the gemcitabine and MMC 
arms, respectively, at a median follow-up of 36 months.98 
A recent single-arm prospective trial utilizing gemcitabine 
in 20 patients with BCG-refractory NMIBC revealed 55% 
disease recurrence at a median follow-up of 15.2 months. 
In this series, the authors reported a mean time to first 
 recurrence of 3.5 months, and 45% of patients with recurrent 
disease exhibited disease progression.99 While promising as 
both a primary and adjuvant therapy, further prospective 
 comparisons with contemporary agents are warranted, and 
at this time gemcitabine is limited to conservative use in 
selected cases of intravesical treatment failure.6,9
Anthracyclines
Doxorubicin, epirubicin, and valrubicin are anthracycline 
antibiotics that prevent protein synthesis by binding DNA 
base pairs and inhibiting topoisomerase II.9,100 While side 
effects including chemical cystitis, decreased bladder capac-
ity, hematuria, and post-instillation fever have hampered the 
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use of doxorubicin, the synthetic derivatives epirubicin and 
valrubicin show similar therapeutic efficacy with better local 
toxicity profiles.9,101 Five early trials randomizing patients to 
intravesical doxorubicin or TUR alone reported an average 
recurrence rate of 38% with doxorubicin compared with 53% 
for TUR, with no benefit shown for disease progression.6,9,69 
Studies comparing epirubicin and valrubicin with TUR 
alone have reported disease recurrence rates comparable 
with doxorubicin.78,101 Randomized controlled trials have 
demonstrated that recurrence rates following administra-
tion of doxorubicin and epirubicin are inferior to BCG,102,103 
which has limited anthracycline use in most early studies 
to immediate postoperative instillation, BCG-refractory 
disease, and CIS.9
Small trials have indicated that a single perioperative dose 
of epirubicin reduces disease recurrence compared with IFN 
or TUR alone.104 In a small series of patients with NMIBC 
randomized to perioperative epirubicin, induction epirubicin, 
or induction MMC with five years of follow-up, Liu et al 
reported similar recurrence rates and minimal toxicity in 
the perioperative epirubicin arm, suggesting that a single 
perioperative dose of epirubicin may be the most efficacious 
means of preventing TCC recurrence in the short term with 
minimal adverse effects.9,105 However, the superiority of 
BCG was demonstrated in a recent randomized prospective 
trial comparing BCG with the combination of epirubicin and 
IFN α2b for the adjuvant treatment of high-grade T1 tumors. 
Sixty-two percent were disease-free in the combination arm 
as opposed to 73% in the BCG arm at 24 months’ follow-up, 
although there were no differences regarding progression and 
adverse events between groups, and the subgroup analysis 
showed that the superiority of BCG was mainly in those 
with concomitant CIS.106 Sequential instillation therapy 
with doxorubicin in combination with MMC has been 
investigated in a small series.6,9 Sekine et al randomized 
42 patients with NMIBC to either BCG or doxorubicin with 
MMC. Initial response rates (86% versus 81%) were equal 
between groups and, with a mean follow-up of 47 months, 
only five patients developed disease progression.107 A recent 
multi-institutional study investigated the use of valrubicin 
in 90 patients with refractory CIS, 60% of whom had failed 
three or more intravesical agents. The findings of this study 
demonstrated that 21% of patients had a complete response, 
10% remained disease-free over a follow-up of 10 years, and 
56% progressed to cystectomy.108 Based on these data, use 
of anthracyclines has been widely accepted overseas, dem-
onstrating the most utility in patients with NMIBC and CIS 
who have failed or are intolerant to BCG therapy.6
Apaziquone
Apaziquone is an indoloquinone bioreductive alkylating 
agent that results in cell death via the redox cycle and alky-
lation of DNA.109 The relative stability of the compound 
and rapid pharmacokinetic elimination of the drug make it 
an intriguing agent for use in NMIBC, and Phase I/II trials 
have confirmed minimal local and systemic toxicity.9,110,111 
In a recent update of their Phase I study, Jain et al reported 
that of the eight patients who achieved a complete response, 
50% relapsed over a median follow-up of 31 months. Of note, 
the recurrence-free interval significantly increased following 
apaziquone administration compared with historic recurrence 
intervals pretreatment.112 In the largest clinical experience to 
date, Van der Heijden et al administered six weekly instil-
lations of 4 mg/40 mL apaziquone to 46 patients with Ta-1, 
G1–2 NMIBC following TUR.6 Two-thirds of subjects dem-
onstrated a complete histologic response rate at 2–4 weeks, 
with local side effects comparable with those of other che-
motherapy instillations.9,113 With longer follow-up, of the 
31 patients who achieved a complete response, observed 
recurrence-free rates at one and two years were 56.5% and 
49.5%, respectively.114 These initial data support apazi-
quone’s promise as an intravesical agent, and Phase III trials 
investigating its use during immediate postoperative instilla-
tion and post-TUR induction therapy are underway.6
Taxanes
Docetaxel and its close relative, paclitaxel, are from a class 
of cytotoxic agents (taxoids) that inhibit the polymeriza-
tion of microtubules by promoting intracellular bundling, 
resulting in M-phase cell cycle arrest and cell death.9,100 The 
systemic administration of taxanes have resulted in antitumor 
activity in metastatic bladder cancer,115 and recent in vitro 
studies have demonstrated their efficacy in TCC cytotoxicity 
assays as well.9,116 In a Phase I trial of six weekly docetaxel 
treatments in 18 patients with recurrent NMIBC who had 
failed at least one intravesical therapy, McKiernan et al 
reported a complete response rate of 56% at post-treatment 
cystoscopy and biopsy, with minimal local toxicity.6,9,117 
Long-term clinical outcomes in this cohort revealed 22% 
and 17% complete and partial response rates, respectively, 
while 61% failed treatment at a median follow-up of 
48.3 months.118 In a recent update of their series of 33 patients 
with refractory NMIBC, Barlow et al reported a 61% com-
plete response rate after six weeks of induction therapy, and 
one- and two-year  recurrence-free survival rates were 45% 
and 32%,  respectively.119 Taxoids are attractive candidates 
for intravesical therapy due to their potency, high molecular 
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weight (853.9–861.9 kDa), and lipophilicity.6 However, poor 
aqueous solubility has previously limited their practicality 
for intravesical administration. Current studies investigating 
the feasibility of bioadhesive polymicropheres to optimize 
paclitaxel release and adhesion to the urothelium in murine 
models are in progress and will be discussed later in this 
review.9,120
Suramin
Suramin is a polysulfonated naphthylurea and a potent 
antagonist of vascular endothelial growth factor (VEGF).109 
Previous studies have demonstrated that increased VEGF 
levels in primary superficial tumors or in urine are associated 
with early recurrence or stage progression,121 and identi-
fied VEGF as a possible candidate for targeted therapy in 
NMIBC.9 Suramin was shown to inhibit the activity of several 
angiogenic factors produced by bladder cancer cell lines, as 
well as cell proliferation, during in vitro studies.122 Inhibition 
of invasion of bladder cancer cell lines with suramin was also 
demonstrated in a bladder tissue explant model.123 Although 
serious metabolic, hematologic, renal, and neurologic seque-
lae have been reported following systemic administration of 
suramin, its high molecular weight (1429 kDa) should prevent 
systemic absorption during intravesical administration.109 
In an open-labeled, nonrandomized dose escalation Phase 
I trial, Ord et al administered six weekly intravesical doses 
of Suramin (10–150 mg/mL in 60 mL saline) to 12 patients 
with a history of recurrent NMIBC.9,124 Findings demonstrate 
minimal evidence of local or systemic toxicity, and Phase II 
trials are currently in the preparatory phase.6
Optimizing efficacy  
of current agents
The unique properties of the bladder render it an ideal organ 
for regional therapy (Table 3). Access per urethra is non-
invasive, and the urothelium provides a barrier preventing 
the systemic absorption of most small-molecule drugs.6,9 
However, with topical therapies, cell kill is proportional 
to the duration of exposure and drug concentration rather 
than dosage.6,125 Current goals for improving the efficacy 
of intravesical therapy are maximizing tumor exposure to 
the therapeutic agent and limiting systemic exposure and 
host toxicity.6,9 Intravesical drug disposition is variable, 
and is affected by drug properties (molecular weight, and 
hydrophilicity, lipophilicity), urine volume and pH, patient 
hydration status, and urothelial integrity.9,57
Drug concentration in the bladder is dependent on dose, 
volume of dosing solution, urine production, and the residual 
urine volume during instillation.6 Response rates with  differing 
chemotherapeutic agents are variable, and several techniques 
have been employed to increase drug concentration and to 
enhance drug delivery. Completely emptying the bladder prior 
to drug administration, repositioning the catheter, or frequently 
changing patient position can help to avoid excessive residual 
urine volumes.9,126 In addition, patients should be encouraged to 
retain the instilled agent for as long as possible, with a  two-hour 
urothelial contact time as an optimal goal.57
Decreasing urine production  
and urine alkalinization
Optimization regimens have been established to maximize 
the effectiveness of MMC. A six-hour fasting period prior to 
instillation, reported to decrease urine volume and prevent 20% 
of drug dilution, is currently recommended in the European 
Association of Urology guidelines for NMIBC.9,127 Cliff et al 
reported a 38% increase in intravesical MMC concentration 
following the administration of 0.2 mg of oral desmopressin 
one hour prior to instillation;128 however, care must be taken in 
patients with cardiac failure or hyponatremia, and widespread 
use has not gained acceptance.6,9 Alkalinizing the urine with 
oral bicarbonate has also been shown to improve MMC drug 
stability, cellular uptake, and muscle penetration.57
Based on results from pharmacokinetic modeling that 
described drug disposition in urine and bladder tissues, 
the International Mitomycin C Consortium synthesized an 
optimized MMC treatment protocol that was tested in a 
multicenter, two-arm Phase III clinical trial.6 Patients in 
the optimized arm received a 40 mg dose of MMC with 
pharmacologic manipulations to maximize drug delivery 
(ultrasound-guided bladder emptying, voluntary dehydra-
tion, and urine alkalinization with sodium bicarbonate) 
and patients in the standard arm received a 20 mg dose in 
a 20 mL dosing volume without manipulations.6 Using a 
primary endpoint of time to recurrence and a secondary 
end point of recurrence-free rate, those in the optimized 
arm  demonstrated a significantly increased median time to 
recurrence (29.1 versus 11.8 months, P , 0.001) and a 19.1% 
increase in five-year recurrence-free rates.9,126
increasing bladder wall penetration
A number of novel chemical and physical approaches have 
been utilized in an effort to increase bladder wall penetration 
and enhance chemotherapeutic efficacy.6,9 It is important to 
note that while these techniques are promising, their effi-
cacy in humans remains to be determined, and the findings 
 presented need to be interpreted with caution.6,9
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Table 3 Optimization of intravesical therapy for NMiBC
Method Mechanism Side effects
Permeation enhancers
 DMSO Promotes urothelial penetration of water soluble  
and lipophilic drugs 
Promotes systemic drug absorption 
and urine production
 Chitosan Cationic polysaccharide rearranges cellular  
junction and enhances paracellular drug transport
Promotes systemic absorption
 Polycarbophil Mucoadhesive polyacrylic acid cross-linked  
with divinyl glycol chelates 
extracellular calcium ions and opens  
cellular tight junctions
Promotes systemic absorption
 Hyaluronidase Hydrolyzes hyaluronan in bladder mucosa  
extracellular matrix; direct tumor suppression
High concentrations may promote  
tumor growth 
 electromotive therapy Temporarily breaches bladder urothelium increased plasma absorption
 Hyperthermia enhances DNA damage and inhibition of DNA  
synthesis, alters intracellular drug trafficking and  
distribution 
increased local irritation
 Photodynamic therapy Accumulation of a photosensitizing agent  
facilitates selective tumor destruction following  
exposure to light 
Skin hypersensitivity, detrusor  
scarring and contracture
Prolonging residence time
 Bio-adhesive microspheres Sustained-retention delivery depots extend  
drug exposure in the bladder cavity
Not yet evaluated in humans
 Magnetic targeting external magnets localize drug-containing  
magnetic micro- and nano-particles in tumors
Unknown; nonspecific localization  
of magnetic particles
 Oral bicarbonate Urine alkalinization improves drug stability and  
cellular uptake
Few
Chemical methods of increasing bladder wall perme-
ability include use of dimethyl sulfoxide (DMSO), chitosan, 
polycarbophil, and hyaluronidase.57 Initially utilized in the 
treatment of patients with interstitial cystitis, DMSO has 
been shown to induce and alter inflammatory tissue responses 
and neurotransmission. DMSO is a bipolar molecule that 
is highly miscible with water, lipids, and organic agents.6,9 
Its ability to cross cellular membranes led to increased 
interest in the coadministration of DMSO with intravesi-
cal agents to promote the penetration of water- and lipid-
soluble drugs. Initial efforts with cisplatin, doxorubicin, 
and paclitaxel showed promise.129 However, DMSO also 
resulted in increased urine production, as well as promoting 
systemic absorption of paclitaxel,129 which has dampened 
initial enthusiasm.  Permeability  enhancers that enhance 
drug transport by rearrangement of cellular tight junctions 
(chitosan, polycarbophil) or hydrolyzation of the bladder 
mucosal hyaluronan network (hyaluronidase) have also been 
investigated.9 In a porcine study, chitosan and polycarbophil 
were shown to increase bladder wall tissue penetration of 
pipemidic acid.130 Coadministration with hyaluronidase has 
been shown to reduce recurrence significantly in patients 
with NMIBC treated with MMC, without increasing systemic 
absorption.131
Physical methods to enhance permeability by urothelial 
disruption include hyperthermia, electromotive therapy, and 
photodynamic therapy.6,9 Hyperthermia has been shown to 
enhance the efficacy of chemotherapeutic agents on  inhibition 
of DNA synthesis and repair, increasing cell membrane 
permeability, and altering intracellular drug transport.109 
Colombo et al evaluated the effectiveness of neoadjuvant 
local bladder hyperthermia in combination with MMC in 
29 patients compared with 23 patients receiving MMC 
alone.6 All patients underwent TUR one week following 
therapy, and a pathologic complete response was observed 
in 66% versus 22% of patients, respectively (P , 0.01).132 
This study was followed by a prospective, multicenter, 
 randomized trial in which 42 patients with intermediate- and 
high-risk NMIBC received MMC in combination with local 
microwave-induced hyperthermia and 41 patients received 
MMC alone following TUR.9 With a minimum follow-up 
of 24 months, recurrence rates were significantly reduced in 
the combination therapy arm compared with the MMC alone 
arm (17.1% versus 57.5%, P = 0.002) respectively.133 The 
efficacy of local bladder hyperthermia in conjunction with 
intravesical chemotherapy has been confirmed in an addi-
tional single-arm series of patients with NMIBC.134 While 
these early results show exciting promise, trials comparing 
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adjuvant microwave hyperthermia and MMC with single 
postoperative MMC instillation or adjuvant BCG are needed 
to define a true disease-recurrence benefit before it can be 
accepted as first-line therapy.6,9
Electromotive drug administration (EMDA), utilizing 
iontophoresis to create a potential difference across the 
bladder wall, has been shown to increase drug transport 
through biologic membranes and to enhance the effective-
ness of intravesical agents when compared with passive 
administration alone.6,9 In a pilot study of 28 patients with 
high-risk NMIBC treated with EMDA-MMC versus MMC 
alone, complete response rates were equivalent, but a lower 
recurrence rate and disease-free interval were observed in 
the combination therapy arm.9,135 Di Stasi et al prospectively 
randomized 108 patients with high-risk NMIBC following 
TUR to EMDA-MMC, MMC alone, or BCG alone. Compared 
with MMC alone, the EMDA-MMC-treated arm showed a 
significant improvement in six-month recurrence-free rate 
(58% versus 31%, P = 0.01) and median time to recurrence 
(35 versus 19.5 months, P = 0.01), and equivalent rates 
compared with the BCG treatment arm.9,136 A subsequent 
trial randomized 212 patients with T1 TCC to BCG alone 
versus BCG followed by three cycles of EMDA/MMC.6 
With a median follow-up of 88 months, patients treated 
with BCG followed by EMDA/MMC had lower recurrence 
rates (41.9% versus 57.9%, P = 0.001), and an increased 
disease-free interval (69 versus 21 months, P = 0.001) when 
compared with BCG alone.137 Di Stasi et al recently presented 
data describing a new concept of preoperative recurrence 
prophylaxis with one single intravesical EMDA/MMC 
instillation immediately prior to TUR. In this prospective 
study, 167 patients with pTa G1-G2 bladder tumors were 
randomized to TUR alone, TUR + one single postoperative 
MMC instillation, or intravesical EMDA/MMC prior to TUR. 
With a median follow-up of 84.7 months, recurrence rates 
following  preoperative EMDA/MMC (37%) were superior 
to TUR alone (67%), and MMC post-TUR (54%, P = 0.007) 
which indicates that new therapeutic strategies may result in 
improved remission rates.9,138
Photodynamic therapy (PDT) is emerging as an  intriguing 
alternative treatment option.6 Based on the premise that 
accumulation of a photosensitizing agent in tumor cells may 
facilitate more selective destruction of malignant cells fol-
lowing exposure to light, early studies focused on porphyrin 
mixtures (Photofrin®) and hematoporphyrin derivatives.9 
Although response rates were encouraging, undesirable 
side effects including prolonged skin hypersensitivity and 
detrusor scarring and contracture discouraged its use.139 
Subsequent trials of 5-aminolaevulinic acid (ALA), a 
precursor of the photosensitizer protoporphyrin IX, have 
shown that local and systemic (hypotension, tachycardia) 
toxicity could be avoided with intravesical administra-
tion.140 Berger et al administered 5-ALA (50 mL) in a 3% 
concentration intravesically in 31 patients with recurrent 
NMIBC (32% BCG-refractory). With a mean follow-up 
of 23.7 months, treatment was well tolerated, and 48% of 
patients developed tumor recurrence. Due to the favorable 
side effect profile, the authors concluded that PDT could be 
applied safely in patients with recurrent bladder cancer who 
had failed BCG therapy or had comorbidities precluding more 
invasive surgical therapy.6,9,141 Current work to determine 
optimal ALA concentration and light energy required for 
effective ALA-PDT eradication is ongoing.140
Prolonging residence time  
and site-directed targeting
Prolonging bladder mucosal exposure to intravesically 
administered chemotherapy is a major challenge, due to agent 
insolubility in the aqueous form and immediate evacuation 
with voiding.6 Sustained-retention delivery platforms offer 
the promise of extending drug exposure in the bladder cavity 
beyond the voiding of urine.57 Bioadhesive microspheres and 
hydrogel systems have been tested in experimental models 
and have been shown to prolong bladder retention of agents, 
including paclitaxel120 and adriamycin,142 to promote urothelial 
absorption.9 Liposomes, positively-charged multilamellar lipid 
vesicles, have been utilized in animal models to enhance the 
intravesical delivery of hydrophobic agents such as capsaicin,143 
currently being investigated in animal studies to facilitate intra-
vesical drug delivery.6 Further studies are necessary prior to 
human trials, but sustained-retention delivery platforms show 
exciting potential in improving intravesical drug delivery.9
Magnetically-targeted carrier therapy utilizes a magnet 
placed externally on the skin covering a predetermined 
bladder site to localize drug containing magnetic par-
ticles in tumors and provide prolonged exposure to higher 
drug concentrations.6,9 Magnetically-targeted carriers are 
microparticles containing metallic iron to increase magnetic 
susceptibility and activated carbon to facilitate binding of the 
chemotherapeutic agent. In a porcine model, Leakakos et al 
demonstrated the feasibility of the intravesical administration 
of doxorubicin utilizing 300–800 mg magnetic particles.6 
Plasma doxorubicin concentrations were below the level 
of detection, and histologic studies confirmed targeted 
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microparticle localization in superficial and deep bladder 
tissue.144 While still in the initial investigatory period, this 
technology shows promise, particularly for bladder preserv-
ing protocols, and warrants further study.6,9
Early radical cystectomy
There is increasing evidence that intravesical chemotherapy, 
while effectively reducing recurrence rates, does not show 
a disease-progression or survival benefit in patients with 
NMIBC.6 In addition, recent data has shown a disturbing 
trend towards decreasing disease-free survival rates in 
patients with T1 disease undergoing radical cystectomy fol-
lowing intravesical therapy.145 Of significant concern in these 
patients is the high prevalence of clinical understaging,7 
which supports the consensus that the timing of radical 
cystectomy for high-grade NMIBC is critical to prognosis 
and long-term survival.6,9 Early cystectomy has been shown 
to result in better outcomes in patients with BCG-refractory 
T1 disease as well as CIS.33 Restaging TUR in patients 
with T1 disease is mandatory,7 especially in patients with 
evidence of disease recurrence.6 Furthermore, the case 
for performing early cystectomy in appropriate surgical 
candidates is strengthened by recent reports demonstrating 
improved perioperative morbidity and mortality rates,32 as 
well as improved patient satisfaction following orthotopic 
urinary diversions.6,9,146 While intravesical therapy is an 
important component of the oncologist’s armamentarium 
in the treatment of superficial bladder cancer, a radical 
cystectomy should be considered in all patients who have 
failed conservative management or who have T1 high-grade 
disease and tumor characteristics with high prognostic risk 
for recurrence.6,9
Conclusion
Bladder cancer is a prevalent disease with significant asso-
ciated health care costs and social implications. The high 
rates of disease recurrence and progression and the need for 
lifetime surveillance impart a large financial and emotional 
burden on the health care system and patients diagnosed with 
bladder cancer. Following diagnosis, prompt repeat TUR 
represents the current standard of care to accurately stage 
patients and to identify patients who may benefit from early 
extirpative surgery. For patients with low volume Ta tumors, 
a single perioperative dose of intravesical chemotherapy is 
recommended by the AUA, and may provide a durable cure 
in many patients. The use of induction and maintenance BCG 
is recommended in patients with intermediate and high risk 
noninvasive disease, and may prevent disease recurrence and 
progression. For patients with muscle invasive disease, radical 
cystectomy remains the gold standard. Early radical cystec-
tomy with continent diversion remains the gold standard 
for the treatment of muscle invasive disease, but may also 
improve quality of life and oncologic efficacy in patients with 
high grade T1 tumors with aggressive prognostic features, 
and should be considered as definitive first line thearpy.
For patients with NMIBC refractory to intravesical 
 chemotherapy, radical cystectomy should be performed 
in appropriate surgical candidates. Unsuitable surgical 
candidates and BCG intolerant patients present a manage-
ment dilemma. Reduction in BCG dosing limits local and 
systemic side effects and improves tolerability, but may 
compromise cancer control. Large meta-analyses have dem-
onstrated the efficacy of chemotherapeutic agents including 
MMC, thiotepa, and doxorubicin as alternatives to BCG in 
preventing disease recurrence compared with TUR alone.6 
Urine alkalinization, dehydration, and bladder emptying may 
improve the efficacy of currently available agents. Alter-
natively, photodynamic, gene, and electromotive therapies 
are emerging device-assisted technologies that may further 
optimize current treatments. Cytotoxic agents including gem-
citabine, valrubicin, and BCG plus IFN as salvage therapy are 
currently under investigation, and have exhibited promising 
early efficacy. Apaziquone, taxoids, and suramin are the 
newest agents under investigation, but it will take several 
more years to compare their efficacy and superiority, if any, 
to current treatments. The ideal agent for the treatment of 
NMIBC remains unidentified, however a number of novel 
therapies appear promising, and we anticipate further signifi-
cant advances concomitant with forthcoming discoveries.
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